EUVIMEDEUVIMED entdecken
Open Access

Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes

Kentaro Sakaki, Takaaki Murakami iD, Hayao Yoshida, Daisuke Otani, Kanae Kawai Miyake, Yoichi Shimizu, Hiroyuki Fujimoto, Daisuke Yabe, Yuji Nakamoto, Nobuya Inagaki

Diabetes · 01.05.2026 · 75 (5) · 787-798

DOI: 10.2337/db25-1127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 12.03.2026. Verfasst von Kentaro Sakaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, Japan Association for Diabetes Education and Care, Advanced Science, Technology & Management Research Institute of KYOTO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Noninvasive measurement of pancreatic β-cell mass remains an important unmet need in type 1 diabetes because conventional surrogate markers, such as C-peptide, often lack sensitivity in advanced disease. This study evaluated the glucagon-like peptide 1 receptor–targeted positron emission tomography tracer, 18F-labeled exendin-4–based probe conjugated with polyethylene glycol, [18F]FB(ePEG12)12-exendin-4 (18F-exendin-4), to determine its ability to visualize pancreatic β-cell mass. Positron emission tomography/computed tomography performed at 60 and 120 min after tracer injection in individuals with type 1 diabetes was compared with data from healthy control participants. No serious adverse events occurred. Pancreatic uptake was consistently lower in individuals with type 1 diabetes and showed clear separation between individuals with insulin-dependent diabetes and healthy control participants at 120 min. Pancreatic uptake at 120 min correlated with fasting C-peptide index and inversely with hemoglobin A1c and daily insulin dose per body weight. These findings support [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography as a noninvasive approach for assessing β-cell mass and disease status. Article Highlights We undertook this study to address the persistent need for noninvasive assessment of β-cell mass in type 1 diabetes. We aimed to determine whether 18F-exendin positron emission tomography/computed tomography can reliably visualize residual β-cell mass and distinguish stages of disease. We found that pancreatic tracer uptake was consistently reduced in type 1 diabetes, differentiated insulin-dependent patients from control participants, and aligned with markers of β-cell function and glycemic status. Our findings suggest that 18F-exendin imaging may offer fundamental platform for disease staging, therapeutic monitoring, and individualized care

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin-Secreting CellsHumansMaleFemaleAdultPositron Emission Tomography Computed TomographyGlycemic ControlC-PeptideExenatideBlood GlucoseGlycated HemoglobinMiddle AgedPeptidesFluorine Radioisotopes

Substanzen

C-PeptideExenatideBlood GlucoseGlycated HemoglobinPeptidesFluorine Radioisotopes

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Radioisotope Research Center, Agency for Health, Safety and Environment, Kyoto University, Kyoto, Japan.
  • Medical Research Institute, Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.

ORCID-Profile: Takaaki Murakami

Förderung

  • Japan Society for the Promotion of Science
  • Japan Association for Diabetes Education and Care
  • Advanced Science, Technology & Management Research Institute of KYOTO
  • Suzuken Memorial Foundation
  • Suzuki Manpei Diabetes Foundation
  • Fujiwara Memorial Foundation
  • Moriya Scholarship Foundation
  • Japan Diabetes Foundation

Zitieren

APA

Sakaki, K., Murakami, T., Yoshida, H., Otani, D., Miyake, K. K., Shimizu, Y., Fujimoto, H., Yabe, D., Nakamoto, Y., & Inagaki, N. (2026). Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes. Diabetes, 75(5), 787-798. https://doi.org/10.2337/db25-1127

Vancouver

Sakaki K, Murakami T, Yoshida H, Otani D, Miyake KK, Shimizu Y, et al. Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes. Diabetes. 2026;75(5):787-798. doi:10.2337/db25-1127

BibTeX
@article{Sakaki2026,
  author = {Sakaki, Kentaro and Murakami, Takaaki and Yoshida, Hayao and Otani, Daisuke and Miyake, Kanae Kawai and Shimizu, Yoichi and Fujimoto, Hiroyuki and Yabe, Daisuke and Nakamoto, Yuji and Inagaki, Nobuya},
  title = {Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {5},
  pages = {787--798},
  doi = {10.2337/db25-1127}
}
Kostenlos starten →